Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Impact of splice-site mutations of the human MDR1 cDNA on its stability and expression following retroviral gene transfer

Gene Therapy volume 10, pages 1061–1065 (2003)Cite this article

Abstract

The multidrug resistance 1 (MDR1) gene transfer to hematopoietic cells for protection against cytotoxic drugs has received considerable attention in gene therapy. However, ectopic expression of MDR1 from retroviral vectors has been hampered by its genetic instability resulting from cryptic splice sites within the cDNA. We have evaluated the efficiency of retroviral MDR1 vectors with introduced mutations of the MDR1 cryptic splice donor (cSD) located at nucleotide +339 and of the cryptic splice acceptor (cSA) at nucleotide +2319 of the cDNA. Sequence alterations of the cSD reduced the expression of MDR1 P-glycoprotein (P-gp), even when generated as silent mutations. A silent mutation of the cSA reduced the splicing activity shifting the splice acceptor site one base downstream; however, it significantly improved the expression of P-gp. The incidence of wild-type MDR1 pregenome splicing was markedly reduced when vectors were produced in human 293 packaging cells as opposed to murine PG13 and GP+envAm12. We conclude that complete splice correction of MDR1 in retroviral vectors may only be achieved with extensive alterations of the cDNA or neighboring vector sequences and that the splicing is significantly influenced by the choice of the packaging cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Aran JM, Pastan I, Gottesman MM . Therapeutic strategies involving the multidrug resistance phenotype: the MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy. Adv Pharmacol 1999; 46: 1–42.

    Article  CAS  PubMed  Google Scholar 

  2. Sorrentino BP et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99–103.

    Article  CAS  PubMed  Google Scholar 

  3. Sorrentino BP, McDonagh KT, Woods D, Orlic D . Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice. Blood 1995; 86: 491–501.

    CAS  PubMed  Google Scholar 

  4. Galipeau J et al. A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs. Hum Gene Ther 1997; 8: 1773–1783.

    Article  CAS  PubMed  Google Scholar 

  5. Bunting KD et al. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood 1998; 92: 2269–2279.

    CAS  PubMed  Google Scholar 

  6. Bunting KD, Zhou S, Lu T, Sorrentino BP . Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. Blood 2000; 96: 902–909.

    CAS  PubMed  Google Scholar 

  7. Mickisch GH et al. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 1992; 79: 1087–1093.

    CAS  PubMed  Google Scholar 

  8. Carpinteiro A et al. Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice. Int J Cancer 2002; 98: 785–792.

    Article  CAS  PubMed  Google Scholar 

  9. Sellers SE et al. The effect of multidrug-resistance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells. Blood 2001; 97: 1888–1891.

    Article  CAS  PubMed  Google Scholar 

  10. Devereux S et al. Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood stem cell transplantation for lymphoma. Gene Therapy 1998; 5: 403–408.

    Article  CAS  PubMed  Google Scholar 

  11. Hesdorffer C et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998; 16: 165–172.

    Article  CAS  PubMed  Google Scholar 

  12. Rahman Z et al. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res 1998; 4: 2717–2721.

    CAS  PubMed  Google Scholar 

  13. Cowan KH et al. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 1999; 5: 1619–1628.

    CAS  PubMed  Google Scholar 

  14. Moscow JA et al. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 1999; 94: 52–61.

    CAS  PubMed  Google Scholar 

  15. Abonour R et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000; 6: 652–658.

    Article  CAS  PubMed  Google Scholar 

  16. Baum C et al. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995; 69: 7541–7547.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Hildinger M, Abel KL, Ostertag W, Baum C . Design of 5' untranslated sequences in retroviral vectors developed for medical use. J Virol 1999; 73: 4083–4089.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Knipper R et al. Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells. Gene Therapy 2001; 8: 239–246.

    Article  CAS  PubMed  Google Scholar 

  19. Hildinger M et al. Dominant selection of hematopoietic progenitor cells with retroviral MDR1 co-expression vectors. Hum Gene Ther 1998; 9: 33–42.

    Article  CAS  PubMed  Google Scholar 

  20. Jelinek J et al. A novel dual function retrovirus expressing multidrug resistance 1 and O6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents. Gene Therapy 1999; 6: 1489–1493.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Internal Grant Agency of Ministry of Health, Czech Republic (NC/5727-3, MZ00237360001) and by the Bundesministerium für Bildung und Forschung (BMBF 01KV9811). CB was also supported by the VolkswagenStiftung.

Author information

Author notes

  1. The first two authors contributed equally

Authors and Affiliations

  1. Institute of Hematology and Blood Transfusion, Prague, Czech Republic

    J Cmejlova, R Cmejla, O Fuchs, D Kalabova & J Jelinek

  2. Heinrich-Pette-Institute for Experimental Virology and Immunology at the University of Hamburg, Germany

    M Hildinger & C Baum

  3. Department of Molecular and Cellular Engineering, Institute for Human Gene Therapy, The Wistar Institute, University of Pennsylvania, Philadelphia, PA, USA

    M Hildinger

  4. Department of Hematology and Oncology, Hannover Medical School, Hannover, Germany

    C Baum

  5. Department of Experimental Hematology, Cincinnati Children's Hospital, Cincinnati, OH, USA

    C Baum

  6. Baylor College of Medicine, Medicine – Hematology/Oncology, Houston, TX, USA

    J Jelinek

Authors
  1. J Cmejlova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Hildinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Cmejla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Kalabova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Baum
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Jelinek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cmejlova, J., Hildinger, M., Cmejla, R. et al. Impact of splice-site mutations of the human MDR1 cDNA on its stability and expression following retroviral gene transfer. Gene Ther 10, 1061–1065 (2003). https://doi.org/10.1038/sj.gt.3301967

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301967

Keywords

This article is cited by

Search

Advanced search

Quick links